Lucentis, developed by San Francisco-based Genentech, is intended to treat individuals with wet age-related macular degeneration and macular edema after retinal vein occlusion — two eye conditions that can impair vision and lead to blindness, according to the report.
The prefilled syringe cuts several steps out of the preparation and administration process for physicians, according to the report.
Genentech expects it to hit the market in early 2017.
More articles on supply chain:
Trucking industry provides less financial support to Donald Trump than past Republican nominees: 4 things to know
Drug industry, hospitals fight over 340B drug pricing program
6 latest FDA approvals
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
